Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Total 2Q 2024 net product revenue of $87.2 million, representing 87% year-over-year growth Auvelity® 2Q 2024 net product sales of $65.0 million, representing 135% year-over-year growth Sunosi® 2Q 2024 net product revenue of $22.1 million representing

By: financialpost.com

Aug 05 2024
0
13013 Views

Axsome is also conducting the ACCORD-2 study, a Phase 3, double-blind, placebo-controlled, randomized withdrawal trial evaluating the efficacy and safety of AXS-05 in AD agitation. The enrollment target for the ACCORD-2 trial has been met and the Company now anticipates topline results in the second half of 2024. Read More

anchor links ads by Easy Branches

Get Reliable Matka Guessing Forum with our Satta Matka Expert and Get all Matka Chart For Free.

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Related

Breckenridge Brewery Opens New Location in Fort Collins, Colorado

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Vietnamese billionaire tycoon found guilty of defrauding stockholders, sentenced to 21 years

Philips to repurchase shares for up to EUR 125 million to cover long-term incentive plans

Gran Tierra Energy Inc. Announces Positive Test Results from Bocachico Norte-J1

Hellish NYC Commutes Reveal Aging Wires Are No Match for Extreme Heat

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

Golden Minerals Announces Chief Financial Officer Retirement and Appoints New Chief Financial Officer

A Gas Carrier Faking Its Location Helps Russia Avoid Sanctions

International Petroleum Corporation Announces Results of Normal Course Issuer Bid

European Stocks Drop Most in Two Years as Global Rout Deepens

Turkish Consumer Inflation Slows at Sharpest Pace Since 2022

Breckenridge Brewery Opens New Location in Fort Collins, Colorado